Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in Women With Previously Untreated Advanced Lung Adenocarcinoma
NCT00137839Phase 2Completed
- Start
- Nov 2004
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC). Primary endpoint: Overall Response Rate at 39 months. Started Nov 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00137839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137839.